Business
Dyadic Announces Leadership Change as Part of Ongoing Strategic Shift to Focus on High Demand Ancillary Proteins for Life Sciences, Nutrition, and Industrial Applications
Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth marketsLeadership team realigned in order to enable execution of ancillary protein strategyDyadic is well positioned to seize on geopolitical tailwinds driving reshoring/friendshoring of biomanufacturing supply chains to the United States and allies abroad JUPITER, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI)
About this update from Dyadic International, Inc.
[{"type":"image","alt":"Dyadic International, Inc.","displaySize":"","headline":null,"caption":"Dyadic International, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":295,"height":229,"url":"https://media.zenfs.com/en/globenewswire.com/346a61dbf291488ea30b6fd65e81e681"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/gy0FmjKeMiJzIWa7r133nQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTMyNjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/346a61dbf291488ea30b6fd65e81e681","width":295,"height":229}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth markets","length":112,"tagName":"p"}]},{"val":[{"type":"text","content":"Leadership team realigned in order to enable execution of ancillary protein strategy","length":84,"tagName":"p"}]},{"val":[{"type":"text","content":"Dyadic is well positioned to seize on geopolitical tailwinds driving reshoring/friendshoring of biomanufacturing supply chains to the United States and allies abroad","length":165,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":361,"olType":false},{"type":"text","content":"JUPITER, Fla., June 02, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI) today announced a leadership change as part of its ongoing strategic shift to evolve into a revenue-generating provider of ancillary recombinant protein products supporting the life sciences, nutrition, and industrial markets. Dyadic’s Board of Directors, which has overseen and endorsed this strategy, has appointed Joe Hazelton as President, effective immediately. Mr. Hazelton will also continue in his role as Chief Operating Officer.","length":577,"tagName":"p"},{"type":"text","content":"Over the past 18 months, Dyadic has made a deliberate pivot to prioritize near-term commercialization opportunities in high-growth, high-value segments such as cell culture media, DNA/RNA technologies, and non-animal food and nutrition ingredients. This pivot has achieved commercial validation through the consummation of high value transactions in the ancillary protein space, including a develop-and-commercialize partnership with Proliant Health and Biologicals for recombinant human albumin, a collaboration with a non-animal dairy enzyme co...